EMD Serono

MS nursing scholarship fund granted $100K by EMD Serono

The Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC) has received a $100,000 donation from EMD Serono, known as Merck Kgaa outside North America, to honor the foundation’s late CEO June Halper by supporting a nursing scholarship fund in her memory. Halper was a former nurse practitioner…

High Adherence to Rebif Seen With RebiSmart Use, Chats With Doctor

Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to RebifĀ (interferon beta-1a) amongĀ multiple sclerosis (MS)Ā patients using the RebiSmart autoinjector, a two-year observational study shows. This study’s level of treatment adherence ā€” 97.9% ā€” was comparable or superior to the…

#ACTRIMS2022 ā€“ In New Mouse Model, Evobrutinib Shows Efficacy

Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) ā€” and found, in experiments, that treatment with an oral medicationĀ called evobrutinibĀ can lessen disease activity. This new mouse model may help scientists in MS to better study…

At 64, I’m Surprised to Be Scrambling to Mount a Chariot

As usual, Iā€™ve gone for what I hope to be an intriguing headline, because youā€™ve got to grab a reader by any means necessary. If youā€™ve read this far, Iā€™m winning! This saga goes back well over a year, when my neurologist suggested I participate in a clinical trial for…

Trial Will Test Mavenclad for Advanced Progressive MS

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study,Ā ChariotMS (NCT04695080), aims to…

Slipping Over the Event Horizon Into SPMS

Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would…

#AANAM ā€“ Exploring Mavenclad’s Effects on Immune Cells

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā€“22. GoĀ hereĀ to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

#AANAM ā€“ Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. A majority of theĀ relapsing-remitting multiple sclerosis (RRMS) patients givenĀ Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…

Mavenclad Effectively Lowers Relapse Rates, Study Comparing DMTs Finds

MavencladĀ (cladribine) appears to be better at lowering relapse rates during the first two years of disease in relapsing-remitting multiple sclerosis (RRMS) patients than other MS therapies, including interferon, Copaxone (glatiramer acetate) and Tecfidera (dimethyl fumarate), a head-to-head observational study found. Mavenclad, however, was less effective at…

CMSC Announces 4 Winners of Pilot Research Awards for 2019

TheĀ Consortium of Multiple Sclerosis Centers (CMSC) named four scientists the winners of itsĀ Pilot Research Award for 2019, given to support projects thought to advance the CMSCā€™s mission and improve the lives of people with multiple sclerosis (MS). The awards, supported by EMD Serono (known as Merck…

Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says

Genentech‘sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosisĀ (SPMS) amongĀ U.S. neurologists, even though Novartis’Ā MayzentĀ (siponimod) and EMD Serono’sĀ MavencladĀ (cladribine) were approved in March to treat this same MS…